ScreenerHero

EXEL Exelixis, Inc.

NAS · US · Healthcare · Biotechnology · exelixis.com
58.85USD+0.79%Mkt Cap: 14.58B $P/E: 18.56

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatme…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
SMMT
Summit Therapeutics Inc.
$13.78BUSD
TWST
Twist Bioscience Corporation
$13.59BUSD

Key Statistics

Company
Market Cap14.58B USD
Enterprise Value13.79B USD
Revenue (TTM)2.44B USD
Gross Profit2.24B USD
Net Income (TTM)782.57M USD
Revenue/Share9.33 USD
Last Price58.85 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.1K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)18.56
P/E (Forward)13.72
PEG2.56
EV/EBITDA13.52
EV/Revenue5.66
P/S5.94
P/B7.88
EPS (TTM)3.17
EPS (Forward)4.25
52W Range
33.7692% of range61.14
52W High61.14 USD
52W Low33.76 USD
Profitability
Gross Margin96.39%
Oper. Margin39.51%
EBITDA Margin41.89%
Profit Margin33.73%
ROE36.21%
ROA27.51%
Growth
Revenue Growth10.60%
Earnings Growth26.20%
Cash Flow & Leverage
Operating CF884.27M USD
CapEx (TTM)39.93M USD
FCF Margin30.37%
FCF Yield5.07%
Net Debt-673.46M USD
Net Debt/EBITDA-0.66
Balance Sheet
Debt/Equity0.08
Current Ratio3.46
Quick Ratio3.24
Book Value/Sh7.41 USD
Cash/Share3.39 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)53.93 USD
Upside (mean)-8.4%
Target Range41.00 USD – 66.00 USD
41.00-8.4% to mean66.00
# Analysts15
Ownership
Shares Out.247.78M
Float213.60M
Insiders1.85%
Institutions106.77%
Short Interest
Short Ratio12.8d
Short % Float14.56%
Short % Out.10.65%
Shares Short26.40M
Short (prev mo.)28.03M
Technical
SMA 5055.83 (+5.4%)
SMA 20049.08 (+19.9%)
Beta0.42
S&P 52W Chg14.58%
Avg Vol (30d)2.12M
Avg Vol (10d)1.92M
Technical Indicators
RSI (14)58.1
MACD0.8057
MACD Signal0.8156
MACD Hist.-0.0099
BB Upper59.66 USD
BB Middle57.89 USD
BB Lower56.13 USD
BB Width6.11%
ATR (14)1.725 USD
Vol Ratio (20d)1.20x